Search company, investor...

Predict your next investment

Edwards Lifesciences company logo
Corporation
HEALTHCARE | Medical Devices & Equipment / Device Design & Manufacturing
edwards.com

Investments

18

Portfolio Exits

3

Funds

1

Partners & Customers

5

About Edwards Lifesciences

Edwards Lifesciences (NYSE: EW) develops medical equipment and devices. It designs, manufactures, and markets tissue heart valves and related repair products. The company also provides solutions in enhanced surgical recovery, clot management, infection control, anesthesia, hospital administration, annuloplasty rings, catheters, hemodynamic monitoring, and more. It was founded in 1958 and is based in Irvine, California.

Headquarters Location

One Edwards Way

Irvine, California, 92614,

United States

949-250-2500

Want to inform investors similar to Edwards Lifesciences about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Edwards Lifesciences News

FMI Forecasts Prosthetic Heart Valve Market to Surge to US$36.3 Billion by 2032 at an Impressive 11.4% CAGR

Sep 25, 2023

Search jobs 25-Sep-2023 FMI Forecasts Prosthetic Heart Valve Market to Surge to US$36.3 Billion by 2032 at an Impressive 11.4% CAGR The global market for prosthetic heart valves achieved a value of US$10.9 billion in 2021, and it is poised to reach US$12.3 billion by the close of 2022. The increasing incidence of valvular ailments, including aortic stenosis (AS), organic and ischemic (functional) mitral regurgitation, and tricuspid regurgitation, is fueling a substantial demand for prosthetic valves. Projections indicate a robust Compound Annual Growth Rate (CAGR) of 11.4% from 2022 to 2032, culminating in a total market value of US$36.3 billion by 2032. When considering end users, hospitals took the lead in the global prosthetic heart valve market in 2021, commanding an estimated revenue share exceeding 75%. This dominance is expected to persist throughout the forecast period Click Here to Access Your Visuals-Packed Report! According to Future Market Insights, an increasing prevalence of valvular heart disease (VHD) is expected to augment the growth of the global prosthetic heart valve market during the forecast period. Regulatory approval for heart valves, integration of technological advancements, and an increasing number of heart valve implantation procedures are other factors expected to influence the revenue growth of the global prosthetic heart valve market in the next 10 years. However, high costs associated with transcatheter heart valve products, procedure-related risks and complications, and product recalls are some restraints likely to hamper the growth of the global prosthetic heart valve market over the forecast period. Segmentation highlights The global prosthetic heart valve market is segmented on the basis of Product Type (Mechanical Heart Valves, Biological/Tissue Heart Valves, Transcatheter Heart Valves) and End User (Hospitals, Ambulatory Surgery Centres). The Transcatheter Heart Valves product type segment is estimated to be valued at US$ 6,069.1 Mn by 2026 end, registering a CAGR of 13.3% between 2016 and 2026 The Hospitals end user segment accounted for 74.5% market share of the global prosthetic heart valve market in 2015. Rising demand for quicker treatment options and remedies is expected to promote the revenue growth of the Hospitals segment over the forecast period Regional market projections The global prosthetic heart valve market is segmented by region into North America, Latin America Excluding Brazil, Brazil, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), and Middle East & Africa (MEA). The global prosthetic heart valve market is largely prominent in the developed regions. The North America regional market is estimated to witness the highest CAGR of 12.4% during the forecast period followed by the Western Europe regional market at 12.1%. Factors such as legislative openness and inline approval procedures are expected to contribute largely to the revenue generation potential and attractiveness of the Western Europe prosthetic heart valve market. Rising adoption of transcatheter heart valves in geriatric patients for better care is expected to fuel revenue growth in the Japan prosthetic heart valve market over the forecast period. Click for Methodology Details! Vendor insights The report on the global prosthetic heart valve market profiles some of the leading companies dominating the global prosthetic heart valve market. Top market players featured in the global prosthetic heart valve market report are Edwards Lifesciences Corporation, St. Jude Medical, Inc., Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, SYMETIS, LivaNova PLC, CryoLife, Inc., Braile Biomedica, Colibri Heart Valve LLC, and JenaValve Technology, Inc. Leading market players are focussing on delivering differentiated therapies to cardiac patients and are strengthening their foothold in the global prosthetic heart valve market through strategic collaborations and acquisitions. Key competitors covered in terms of prosthetic heart valve market are Edwards Lifesciences Corporation, St. Jude Medical, Inc., Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, SYMETIS, LivaNovaPLC, CryoLife, Inc., Braile Biomedica, Colibri Heart Valve, LLC, and JenaValve Technology, Inc. Key strategies adopted by most of the major players in the global prosthetic heart valve market include: product approvals and commercialisation, leveraging existing capabilities to create patient-centric technologies, briskly entering markets in emerging countries and offering the latest innovative technologies to healthcare facilities and, thus strengthening regional proficiency and addressing customer needs. New product launches, innovation and expansion are anticipated to form the core of these strategies during the forecast period. Get Ahead with Comprehensive Information – Purchase Now

Edwards Lifesciences Investments

18 Investments

Edwards Lifesciences has made 18 investments. Their latest investment was in egnite as part of their Seed on February 2, 2021.

CBI Logo

Edwards Lifesciences Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/10/2021

Seed

egnite

Yes

2

9/23/2020

Series C - II

V-Wave

$28M

No

2

7/15/2020

Series B

Caption Health

$53M

Yes

5

4/26/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

4/13/2016

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/10/2021

9/23/2020

7/15/2020

4/26/2018

4/13/2016

Round

Seed

Series C - II

Series B

Series C

Series A - II

Company

egnite

V-Wave

Caption Health

Subscribe to see more

Subscribe to see more

Amount

$28M

$53M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

5

10

10

Edwards Lifesciences Portfolio Exits

3 Portfolio Exits

Edwards Lifesciences has 3 portfolio exits. Their latest portfolio exit was Caption Health on February 09, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/9/2023

Acquired

$99M

17

2/14/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

9/21/2007

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

2/9/2023

2/14/2017

9/21/2007

Exit

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

17

10

0

Edwards Lifesciences Acquisitions

13 Acquisitions

Edwards Lifesciences acquired 13 companies. Their latest acquisition was Corvia Medical on March 11, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/11/2019

Series E+

$99M

$108.28M

Acquired

2

11/29/2018

$99M

Acquired Unit

1

11/26/2018

$99M

Acquired Unit

1

4/18/2018

Subscribe to see more

$99M

Subscribe to see more

10

12/6/2017

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

3/11/2019

11/29/2018

11/26/2018

4/18/2018

12/6/2017

Investment Stage

Series E+

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$108.28M

$99M

Note

Acquired

Acquired Unit

Acquired Unit

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Edwards Lifesciences Fund History

1 Fund History

Edwards Lifesciences has 1 fund, including Social Impact Investment Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

8/2/2021

Social Impact Investment Fund

$70M

1

Closing Date

8/2/2021

Fund

Social Impact Investment Fund

Fund Type

Status

Amount

$70M

Sources

1

Edwards Lifesciences Partners & Customers

5 Partners and customers

Edwards Lifesciences has 5 strategic partners and customers. Edwards Lifesciences recently partnered with United Parcel Service on May 5, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

5/4/2020

Vendor

United States

UPS Supports Edwards Lifesciences' Distribution Of Critical ICU Monitoring Equipment And Other Medical Technologies

UPS - Get Report today announced as part of its longstanding relationship with Edwards Lifesciences , it continues to help the med-tech company get necessary equipment to hospitals around the world in the ongoing battle against COVID-19 .

3

12/10/2018

Partner

United States

Subscribe to see more

Subscribe to see more

10

6/29/2015

Vendor

United States

Subscribe to see more

Subscribe to see more

10

11/24/2004

Licensor

United States

Subscribe to see more

Subscribe to see more

10

Licensor

United States

Subscribe to see more

Subscribe to see more

10

Date

5/4/2020

12/10/2018

6/29/2015

11/24/2004

Type

Vendor

Partner

Vendor

Licensor

Licensor

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

UPS Supports Edwards Lifesciences' Distribution Of Critical ICU Monitoring Equipment And Other Medical Technologies

UPS - Get Report today announced as part of its longstanding relationship with Edwards Lifesciences , it continues to help the med-tech company get necessary equipment to hospitals around the world in the ongoing battle against COVID-19 .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Edwards Lifesciences Team

15 Team Members

Edwards Lifesciences has 15 team members, including current Chief Executive Officer, Michael A. Mussallem.

Name

Work History

Title

Status

Michael A. Mussallem

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Michael A. Mussallem

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Edwards Lifesciences to Competitors

S
Sotera Wireless

Sotera Wireless is committed to the development, marketing and sale of a new generation early detection surveillance monitoring system. Its flagship product, the ViSi Mobile, is designed to improve patient safety by detecting early signs of deterioration in virtually any care setting, enabling early intervention and rapid response without limiting the patient's freedom of movement

B
BioBeat

BioBeat is a medical technology company. Its remote patient monitoring (RPM) health platform includes a disposable short-term chest-monitor and a long-term wrist-monitor, both of which utilize a photoplethysmography-based (PPG) sensor to provide patient readings of various health parameters, including cuffless blood pressure, pulse rate, respiratory rate, blood oxygen saturation, temperature, stroke volume, cardiac output, and more. The company was founded in 2016 and is based in Petach Tikva, Israel.

Aktiia Logo
Aktiia

Aktiia's technology combines common optical sensors, known for tracking heart-rate in today's wearables, and clinically validated software algorithms to measure an individual's blood pressure at the wrist. The algorithms will be embedded in non-medical third-party wearables for the preventive purpose to track blood pressure trends, as well as in Aktiia's medical grade wearable to monitor precise blood pressure values that can be used for the diagnosis and management of hypertension.

CareTaker Medical Logo
CareTaker Medical

CareTaker Medical operates as a wireless patient monitor. It uses a finger cuff to measure continuous beat-by-beat blood pressure, heart rate, and other physiological parameters enabling remote patient monitoring. CareTaker Medical was founded in 2014 and is based in Charlottesville, Virginia.

KLISBio Logo
KLISBio

KLISBio is a med-tech company. The company develops regenerative implantable products by using silk fibroins. The company leverages a silk-based technology platform to develop scaffold materials for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears, and situations where a sustained drug release is needed. It was founded in 2014 and is based in Milan, Italy.

D
Dynocardia

Dynocardia is a biomedical device development company that has developed ViTrack, a diagnostic device that is a stand-alone, cuff-less device that allows for continuous, non-invasive blood pressure (cNIBP) measurement. ViTrack offers direct, beat-to-beat measurement of blood pressure that is wrist-wearable and mobile. The device has data-rich capabilities such as heart rate, heart rhythm, and respiratory parameters in addition to blood pressure that enables early intervention prior to acute events. The company was founded in 2018 and is based in Cambridge, Massachusetts.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.